IPSEF - Exelixis lead product hits main goal in Phase 3 prostate cancer trial
2023-08-21 07:29:59 ET
More on Exelixis
- Exelixis: Stock Likely To Break Out Of 5-Year Inertia
- Exelixis: Thriving Investment Opportunity In The Evolving World Of Oncology
- Exelixis, Teva settle patent dispute over cancer drug Cabometyx
- Exelixis a new overweight at Piper Sandler on Cabometyx, pipeline
- Exelixis board member resigns; Farallon gets third board seat in victory
For further details see:
Exelixis lead product hits main goal in Phase 3 prostate cancer trial